NAPS2 Neuroimaging Core

NAPS2 神经影像核心

• 批准号: 10674049
• 负责人: KEJAL KANTARCI
• 金额: $ 53.77万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674049
• 关键词: 3-Dimensional; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Atrophic; Brain Stem; Brain imaging; Cell Nucleus; Clinical; Clinical Data; Clinical Research; Collaborations; Collection; Communities; Confidentiality of Patient Information; Corpus striatum structure; Cross-Sectional Studies; Data; Data Collection; Data Set; Dementia with Lewy Bodies; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Disease Progression; Drug Delivery Systems; Ensure; Foundations; Functional Magnetic Resonance Imaging; Functional disorder; Funding; Future; Genetic; Goals; Image; Imaging Device; Investigation; Iron; Laboratories; Language; Longitudinal Studies; Magnetic Resonance Imaging; Maintenance; Maps; Measurement; Measures; Methods; Monitor; Multiple System Atrophy; Nerve Degeneration; Neurodegenerative Disorders; Office of Administrative Management; Outcome; Parasomnias; Parkinson Disease; Participant; Patients; Pattern; Play; Predisposition; Process; Protocols documentation; Quality Control; REM Sleep Behavior Disorder; Radionuclide Imaging; Reproducibility; Research; Research Personnel; Resolution; Resources; Rest; Role; Scanning; Site; Standardization; Substantia nigra structure; Symptoms; Techniques; Testing; Thick; Time; United States National Institutes of Health; Work; basal forebrain; biomarker identification; candidate marker; cerebral atrophy; clinical care; data management; data sharing; dopamine system; experience; genetic information; high risk; image processing; imaging modality; imaging study; innovation; interest; locus ceruleus structure; longitudinal analysis; multimodality; neuroimaging; neuroimaging marker; neuromelanin; neuroprotection; pars compacta; programs; progression marker; prospective; single photon emission computed tomography; sound; synucleinopathy; targeted biomarker; targeted treatment; trial design; uptake; web site

ABSTRACT: NAPS2 NEUROIMAGING CORE The Neuroimaging Core of the North American Prodromal Synucleinopathy Consortium on RBD, Stage 2 (NAPS2) will ensure that state-of-the-art techniques are applied and that innovative analytic techniques are used. The Neuroimaging Core will be directed by leaders in brain imaging in neurodegenerative diseases with extensive experience supporting the imaging needs of multi-site projects. Many of the Core leaders have collaborated with NAPS investigators on prior research in RBD and synucleinopathies. The prior experience and collaborations within the Neuroimaging Core team will ensure a smooth transition of imaging support for NAPS2. Prior imaging studies of RBD are few and have generally been small, retrospective, or single-site investigations. We provide preliminary data to support all of the imaging modalities that will be utilized in the protocol and demonstrate the soundness of the methods proposed. We will prospectively collect and evaluate multimodal MRI and DaTscan imaging data in over 300 participants with RBD longitudinally, at two time points, with innovative methods to support the Project and advance the field. There are several innovative aspects of this Core, including the use of: 1) multi-shell and multi-band imaging acquisition protocols for collection of high resolution dMRI and rs-fMRI data in reasonable acquisition time, harmonized across multiple sites, 2) quantification of iron load with multi-echo gradient echo (GRE) MRI using quantitative susceptibility mapping and R2* relaxometry, 3) quantification of neuromelanin volume in locus coeruleus and substantia nigra pars compacta using a magnetization transfer contrast neuromelanin-sensitive MRI (NM-MRI) approach with automated image processing and high reproducibility, and 4) DaTscan quantitative analysis using semi-automated processing to provide standardized and harmonized region-to-background and z-score data. The Neuroimaging Core aims are to: 1) establish and maintain harmonized MRI and DaTscan SPECT acquisition protocols at the participating sites, 2) operate a standardized quality control program for MRI and DaTscan, including ongoing image quality monitoring, rating and maintenance, and 3) supply processed cross-sectional and longitudinal data on serial MRIs and DaTscans for the Project focused on predicting phenoconversion, and share these data with the research community. This latter aim includes providing cross-sectional and longitudinal data to the Laboratory of Neuroimaging (LONI) for sharing with outside investigators. All images will be anonymized and directly downloadable from the LONI website. Language will be developed on the NAPS2 and LONI websites to guide outside investigators interested in these data. This clinical dataset will be freely downloadable along with the images for researchers who do not require genetic information for their analyses.

摘要：NAPS 2神经成像核心 北美前驱突触核蛋白病联盟关于RBD的神经影像学核心， 第二阶段（NAPS 2）将确保应用最先进的技术，并确保创新的分析方法 技术。神经成像核心将由脑成像领域的领导者指导， 在神经退行性疾病方面拥有丰富的经验，支持多中心项目的成像需求。 许多核心领导人与NAPS调查人员合作进行RBD的先前研究， 共核蛋白病神经影像核心团队的先前经验和合作将确保 NAPS 2成像支持的平稳过渡。先前的RBD影像学研究很少， 小型、回顾性或单中心研究。我们提供初步数据来支持所有的 将在方案中使用并证明方法可靠性的成像模式 提出了我们将前瞻性地收集和评估300多个国家的多模式MRI和DaTscan成像数据。 参与者在两个时间点纵向接受RBD，采用创新方法支持项目， 推进领域。该核心有几个创新方面，包括使用：1）多壳和 多波段成像采集协议，用于以合理的方式收集高分辨率dMRI和rs-fMRI数据 采集时间，在多个部位协调，2）使用多回波梯度回波量化铁负荷 (GRE)使用定量磁化率映射和R2* 弛豫法的MRI，3）神经黑色素的定量 利用磁化传递对比测量蓝斑和黑质的体积 神经黑色素敏感MRI（NM-MRI）方法，具有自动图像处理和高再现性， 和4）使用半自动化处理的DaTscan定量分析，以提供标准化和 协调区域到背景和z分数数据。神经影像核心目标是：1）建立和 在参与研究中心维持协调一致的MRI和DaTscan SPECT采集方案，2）操作 MRI和DaTscan的标准化质量控制程序，包括持续的图像质量监测、评级 和维护，以及3）提供连续MRI和DaTscan的处理后的横截面和纵向数据 该项目的重点是预测表型转化，并与研究界分享这些数据。 后一个目标包括向神经影像学实验室提供横截面和纵向数据 （LONI）与外部调查人员共享。所有图像将匿名，并直接下载从 LONI网站将在国家行动计划2和国家信息网络办事处网站上开发语言， 研究人员对这些数据感兴趣。该临床数据集将与图像一起免费沿着 对于不需要遗传信息进行分析的研究人员。